The GLOW Protocol for dogs
Also searched as: GLOW stack, GHK-Cu BPC-157 TB-500
The short answer
GHK-Cu added to BPC-157 and TB-500 — investigated where skin, coat, and wound healing are part of the picture alongside soft tissue repair.
What it is and why these compounds
GLOW adds GHK-Cu to the Wolverine pairing. The reasoning is coverage: BPC-157 and TB-500 are investigated for deeper soft tissue, while GHK-Cu has the most relevant research in skin and open wounds, though that research is rodent and human rather than canine. It is most often discussed for post-surgical cases where both the incision and the underlying repair matter, or where coat quality is a secondary concern. GHK-Cu can be applied topically, which means the added burden over the Wolverine protocol is often not an extra injection at all.
Compounds in this protocol
A copper-binding tripeptide with the strongest wound-healing evidence here — though none of it in dogs.
The only peptide on this site with published canine pharmacokinetic data.
A thymosin beta-4 fragment studied for tissue repair, and well characterised in equine doping-control literature.
Before starting
These are the decisions that determine whether this protocol is appropriate at all.
⚠ Read first
Bedlington Terriers and certain Labrador lines carry inherited copper storage disease. For these dogs the injectable GHK-Cu route should not be used, and topical is the only route worth considering.
Caution
Any dog with hepatic disease should avoid injectable GHK-Cu regardless of breed.
Caution
TB-500 remains contraindicated with active or suspected cancer.
Caution
Three compounds at once makes attributing an adverse effect close to impossible. Introducing them in sequence is the more cautious approach.
Example timeline
A representative schedule drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Days 1–7Initiation
What owners observe
Apply topical GHK-Cu to the wound or incision twice daily. Begin the injectable components as in the Wolverine protocol. Watch for irritation at topical sites.
Clinical monitoring
Baseline CBC, chemistry, and liver values — the last specifically because of copper handling. Confirm cancer screening for TB-500.
- 2Weeks 2–4Active remodelling
What owners observe
Wound closure visibly accelerating, with coat quality often improving around treated areas. Mobility gains from the injectable components typically become apparent in the same window.
Clinical monitoring
Reassess the wound bed. TB-500 to maintenance at week 3–4. Recheck liver values if injectable GHK-Cu is being used rather than topical.
- 3Weeks 4–8Taper
What owners observe
Discontinue injectables in sequence rather than all at once. Topical GHK-Cu is often continued for chronic dermatologic conditions.
Clinical monitoring
Discontinue injectable GHK-Cu by week 8 at the latest. Recheck liver values if the injectable route was used beyond four weeks.
Investigated for
Common questions
What is the GLOW Protocol for dogs?+
GHK-Cu added to BPC-157 and TB-500 — investigated where skin, coat, and wound healing are part of the picture alongside soft tissue repair. It combines GHK-Cu, BPC-157, TB-500.
Is the GLOW Protocol safe for dogs?+
Bedlington Terriers and certain Labrador lines carry inherited copper storage disease. For these dogs the injectable GHK-Cu route should not be used, and topical is the only route worth considering. Any dog with hepatic disease should avoid injectable GHK-Cu regardless of breed. TB-500 remains contraindicated with active or suspected cancer. Three compounds at once makes attributing an adverse effect close to impossible. Introducing them in sequence is the more cautious approach.
How long does the GLOW Protocol run?+
The example timeline runs from days 1–7 through weeks 4–8. Actual duration should be set by the veterinarian managing the case and adjusted on response.
References
- 1.Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14648529
- 2.Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227353
- 3.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730
- 4.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMID 29986520
- 5.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 6.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 7.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 8.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 9.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 10.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
- 11.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
- 12.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 13.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 14.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
- 15.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.